Open AccessLazarus type response to immunotherapy in three patients with poor performance status and locally advanced NSCLC: a case series and literature review
Author(s) -
Naifu Nie,
Zhulin Liu,
Mingxia Feng,
Lan Liu,
Nuo Luo,
Li Li,
Yong He
Publication year - 2021
Publication title -
annals of palliative medicine
Language(s) - English
Resource type - Journals
eISSN - 2224-5839
pISSN - 2224-5820
DOI - 10.21037/apm-20-2279
Subject(s) - medicine , immunotherapy , oncology , lung cancer , non small cell lung cancer (nsclc) , performance status , intensive care medicine , cancer , overall survival , a549 cell
Immune checkpoint inhibitors (ICIs) have become the standard treatment for patients with advanced non-small cell lung cancer (NSCLC). However, the safety and efficacy of ICIs in severe advanced NSCLC patients with poor performance status (PS) are still unclear.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom